AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
ERENUMAB
8 registrations across 4 African markets— 8 active
Markets with ERENUMAB
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| AERINEX 140mg/ml Solution For Injection In Pre-Filled Syringe | 🇰🇪Kenya | Novartis Overseas Investment AG | active | Feb 2031 |
| PASURTA | 🇬🇭Ghana | — | active | Feb 2027 |
| PASURTA | 🇬🇭Ghana | — | active | Feb 2027 |
| AERINEX 70MG/ML Solution For Injection In Pre-Filled Syringe | 🇰🇪Kenya | Novartis Overseas Investment AG | active | Aug 2026 |
| PASURTA 70 mg/ml | 🇿🇦South Africa | Novartis South Africa (Pty) Ltd | active | Jan 1900 |
| PASURTA 140 mg/ml | 🇿🇦South Africa | Novartis South Africa (Pty) Ltd | active | Jan 1900 |
| Pasurta 70 mg/mL Solution for Injection in a Prefilled Syringe Solution for injection | 🇳🇬Nigeria | — | active | — |
| Pasurta 140 mg/mL Solution for Injection in a Prefilled Syringe Solution for injection | 🇳🇬Nigeria | — | active | — |
ERENUMAB in Africa — Regulatory Overview
ERENUMAB is registered across 4 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Kenya, Nigeria, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 8 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.